ReviewJournal of hepatocellular carcinoma2019
Combined hepatocellular cholangiocarcinoma (cHCC-CC): an update of genetics, molecular biology, and therapeutic interventions.
Review in Journal of hepatocellular carcinoma, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed.
- Comprehensive molecular profiling of combined hepatocellular carcinoma and cholangiocarcinoma reveals distinct Notch signaling subgroups with prognostic significance.Virchows Archiv : an international journal of pathology · 2026Article
- Viral vs. Non-Viral Combined Hepatocellular-Cholangiocarcinoma: Distinct Genomic Landscapes and Survival Outcomes.Journal of gastrointestinal cancer · 2026Article
- Update on the clinical features, treatment and histogenesis of combined hepatocellular-cholangiocarcinoma.Oncology letters · 2026Article
- Differentiating combined hepatocellular-cholangiocarcinoma from mass-forming intrahepatic cholangiocarcinoma with MRI and tumor markers: a multi-center study.European radiology · 2026Article
- Impact of postoperative chemotherapy on the prognosis of combined hepatocellular-cholangiocarcinoma: a retrospective study based on the SEER database.Journal of gastrointestinal oncology · 2025Article
- Establishment and characterization of CHC-X1: the third human combined hepatocellular-cholangiocarcinoma cell line.BMC cancer · 2025Article
- MRI features of combined hepatocellular-cholangiocarcinoma.Abdominal radiology (New York) · 2025Review
- Incidence trends and disparities in infection-related malignancies of the liver among US adults, 2000-2019.Gastroenterology report · 2025Article
- Epigenetic regulation of individual components of combined hepatocellular-cholangiocarcinoma.PloS one · 2025Article
- Sarcomatoid change in combined hepatocellular carcinoma and cholangiocarcinoma as a poor prognostic factor.Journal of gastrointestinal oncology · 2024Article
- A Novel Approach to Quantify Heterogeneity of Intrahepatic Cholangiocarcinoma: The Hidden-Genome Classifier.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Treatments and prognostic outcomes of combined hepatocellular-cholangiocarcinoma with distant metastasis: an analysis based on SEER data.Translational cancer research · 2024Article
- Syngeneic mouse model of YES-driven metastatic and proliferative hepatocellular carcinoma.Disease models & mechanisms · 2024Article
- Combined hepatocellular cholangiocarcinoma: A clinicopathological update.World journal of hepatology · 2024Review
- Efficacy of dual checkpoint inhibitors in a patient with a mixed hepatocellular cholangiocarcinoma.BMJ case reports · 2024Article
- Elucidating hepatocellular carcinoma progression: a novel prognostic miRNA-mRNA network and signature analysis.Scientific reports · 2024Article
- Review
- Current advances and future directions in combined hepatocellular and cholangiocarcinoma.Gastroenterology report · 2024Review
- Advances in Targeted Drug Resistance Associated with Dysregulation of Lipid Metabolism in Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2024Review
- Article
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Combined hepatocellular cholangiocarcinoma (CC) is a rare and aggressive primary hepatic malignancy with significant histological and biological heterogeneity. It presents with more aggressive behavior and worse survival outcomes than either hepatocellular carcinoma or CC and remains a diagnostic challenge. An accurate diagnosis is crucial for its optimal management. Major hepatectomy with hilar node resection remains the mainstay of treatment in operable cases. Advances in the genetic and molecular characterization of this tumor will contribute to the better understanding of its pathogenesis and shape its future management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.